Drug coverage is the part of a benefit plan members use most and the part that costs employers most to run. It is also the part changing fastest. Since 2024 Canada has had a national pharmacare program operating in some provinces and not others, a category of weight and metabolic drugs has become one of the largest cost drivers on private plans, and biologic drugs continue to reshape what a claim can look like.
Here is how prescription drug coverage works in Canada in 2026, what private plans do and do not pay for, and what plan sponsors should be reviewing.
How prescription drug coverage works in Canada
Canada’s universal health insurance covers physician and hospital care, but outpatient prescription drugs sit largely outside it. Drugs given to you in hospital are covered by your provincial health plan. Drugs you fill at a pharmacy generally are not, unless you qualify for a public program or you have private coverage.
That gap is filled by a patchwork. Most working Canadians and their families are covered through an employer group plan. Others rely on provincial programs, individual policies they purchase themselves, or the federal pharmacare program where it operates.
The result is that two people with the same prescription, in different provinces or different jobs, can pay very different amounts for it.
The three sources of Canada drug plans
Public programs. Every province and territory runs its own drug programs, typically aimed at seniors, low-income households, people receiving income support or disability benefits, and people facing catastrophic drug costs. Each has its own formulary, its own eligibility rules and its own cost sharing. Separately, national pharmacare now operates in participating jurisdictions, and the federal Non-Insured Health Benefits program covers eligible First Nations and Inuit clients.
Employer group plans. The most common source of coverage for working Canadians. Group drug coverage is generally broader than individually purchased coverage and is not subject to pre-existing condition exclusions in the way individual policies often are.
Individual policies. Purchased directly from an insurer, usually by people without access to a group plan, the self-employed, or retirees coming off a group plan. Coverage is narrower, underwriting may apply, and an individual policy is generally secondary to a group plan where both exist.
What private pharmaceutical coverage includes
Private pharmaceutical coverage is not open-ended. For a drug claim to be paid, the drug ordinarily has to meet three tests:
- Prescribed by an authorized prescriber. Physicians and dentists, and depending on the province, nurse practitioners and pharmacists with prescribing authorization.
- Medically necessary, as the plan defines it.
- Carry a Drug Identification Number. A DIN is the eight-digit number Health Canada assigns to every drug sold in Canada. It identifies the manufacturer, product name and active ingredients, and it appears on the product label and your pharmacy receipt.
Meeting all three does not guarantee payment. Your plan’s own terms still govern, including deductibles, coinsurance percentages, dispensing fee limits, annual or lifetime maximums, and any drug-specific conditions.
What Canadian drug plans do not cover
Some exclusions are close to universal across private plans:
- Over-the-counter medications, even where a physician has recommended them, since they are not dispensed on prescription.
- Drugs administered in hospital, which fall to your provincial health plan.
- Products without a DIN.
- Compounded preparations in many plans, or only where every ingredient is itself an eligible benefit.
Others vary a great deal by plan, and this is where the old assumptions have shifted most:
- Newly approved drugs. Many plans apply a waiting period or a review process before adding a newly approved product, particularly high-cost specialty drugs.
- Brand-name drugs where a generic exists. Usually reimbursed at the generic price. See generic substitution below.
- Fertility drugs, smoking cessation aids and weight-management drugs. Historically grouped together as “lifestyle” exclusions. That framing no longer reflects the market. Many plans now cover some or all of these, often with conditions attached, and weight-management drugs in particular have moved decisively.
- Contraceptives. Commonly covered by private plans, and covered by national pharmacare in participating provinces and territories.
- Medical cannabis. Some group plans offer coverage, typically through a specific provision with its own annual limit rather than as part of the general drug benefit.
If you want to know where your plan actually stands on any of these, the benefit booklet is the authority, not a general guide.
National pharmacare: what it covers and where
The first phase of national pharmacare covers a range of birth control options and diabetes medications. It pays for listed products and the dispensing fee. It does not cover delivery fees or pharmacist prescribing fees.
Critically, it only operates where the federal government has reached a bilateral agreement with the province or territory. As of Health Canada’s most recent update, those jurisdictions are British Columbia, Manitoba, Prince Edward Island and Yukon.
Alberta is not among them. For Alberta employers, that means contraception and diabetes medications are not covered by federal pharmacare, and coverage for those categories continues to run through employer plans and Alberta’s own programs. If your plan documentation or employee communications assume federal coverage exists, it does not, at least not here and not currently.
This is an area where the position can change. Plan sponsors should treat the list of participating jurisdictions as something to check rather than something to assume, particularly if you employ people in more than one province.
Drug coverage in Alberta
Alberta runs its own set of government-sponsored drug programs, administered by Alberta Blue Cross, with eligibility handled by the Alberta Health Care Insurance Plan.
Coverage for Seniors is premium-free coverage for Albertans aged 65 and over. Non-Group Coverage is a premium-based program for those under 65 that also extends to a spouse and dependents. Both cover prescription drugs listed in the Alberta Drug Benefit List.
For both programs, the co-payment is 30% of the prescription cost to a maximum of $35, effective April 1, 2026. You can pay more than that maximum in a few situations: if the drug is not on the Alberta Drug Benefit List, if you choose a more expensive brand where a least-cost alternative exists, or if the brand you want costs more than the maximum price Alberta has set for it.
For employers, the practical point is where these programs sit relative to your plan. They matter most at the edges of your workforce: employees approaching 65, retirees, and people between jobs. Understanding how your plan interacts with them is part of designing a sensible retiree or termination provision rather than leaving people to discover the answer themselves.
How plans control drug costs
Every plan uses some combination of the following. Knowing which ones your plan uses tells you more about your cost exposure than the headline coinsurance percentage does.
Generic substitution. Where an interchangeable generic exists, the plan reimburses at the generic price. If the member wants the brand, they pay the difference, unless the plan allows an exception on documented medical grounds.
Prior authorization. Specified drugs require the insurer’s approval before they are covered, usually on the basis of a diagnosis, prior treatment history or clinical criteria. Common for specialty and high-cost drugs.
Step therapy. The member must try a lower-cost therapy first and demonstrate it was ineffective or not tolerated before a higher-cost option is funded.
Biologics and biosimilars. A biologic is made from living cells. A biosimilar is a highly similar, lower-cost version available once the originator’s patent protection ends. The cost difference is substantial: originator biologics can exceed $25,000 per patient per year, with biosimilars costing up to half as much.
Alberta’s Biosimilars Initiative requires adult patients on Alberta government-sponsored drug plans to switch from certain originator biologics to the biosimilar version to keep coverage, with patients under 18 not required to switch. It is worth being precise about scope, because this is widely misunderstood: the initiative applies only to government-sponsored plans. It does not apply to private group plans. If your plan covers biologics and you have no biosimilar position of your own, you are absorbing the originator price by default.
Maximums and caps. Annual or lifetime limits on the drug benefit overall or on specific categories.
Pooling. Very high-cost recurring claims can be pooled across plans so a single catastrophic claim does not destabilize one employer’s renewal. Our explanation of how drug pooling works covers the mechanics.
GLP-1 drugs and what they are doing to plan costs
If you have looked at a renewal in the last two years, you have seen this category.
GLP-1 therapies were originally diabetes drugs. Their approved uses have since broadened into chronic weight management and cardiovascular risk reduction, with further indications emerging. Alberta Blue Cross’s 2026 drug pipeline analysis identifies them as a major cost driver on employer-sponsored plans and expects that pressure to continue as indications expand, as newer therapies arrive, and as oral formulations become available.
The scale is visible in public plan data too. The Canadian Institute for Health Information has reported that Ozempic became the single largest contributor to growth in public prescription drug spending, accounting for roughly $807 million of $20.1 billion in public plan spending and around 8.5 percentage points of a 9.2% annual increase.
Employer practice is shifting rather than settling. Survey data published by the International Foundation of Employee Benefit Plans in 2026 found:
- 51% of Canadian employers cover GLP-1s for diabetes only, down from 56% in 2025 and 66% in 2024
- 37% cover them for both diabetes and weight loss, up from 31% in 2025 and 17% in 2024
- 12% cover them for other conditions, including sleep apnea and cardiovascular disease
Among employers covering weight-loss indications, 85% do so through the prescription drug plan, 12% through a dedicated weight-management provider, and 4% through a supplemental drug rider.
Where coverage exists for weight management, it usually comes with conditions: prior authorization, clinical eligibility criteria, and a requirement to have tried other approaches first. Some sponsors have added annual caps. Others have carved the category out entirely. A third group treats it as part of a broader chronic disease and disability prevention strategy, on the reasoning that the downstream costs of untreated metabolic disease also land on the plan, and on disability.
A generic version of semaglutide is expected to reach the Canadian market during 2026, which should provide some relief in that specific molecule. It is unlikely to reverse the category trend, given how many products and indications are behind it.
There is no single correct answer here. There is a decision, and it should be made deliberately, with the numbers in front of you, rather than arrived at by whichever way the claims happen to fall.
What plan sponsors should review in 2026
- Where do your people live? If you employ across provinces, federal pharmacare covers some of them and not others, and your provincial program interactions differ by jurisdiction.
- What is your GLP-1 position, and is it written down? Whether you cover, cover with conditions, or exclude, the decision should be explicit and communicated. The worst version is silence followed by inconsistent adjudication.
- Do you have a biosimilar position? Alberta’s provincial policy does not extend to your plan.
- What are your prior authorization and step therapy provisions actually doing? These are the levers with the most cost effect and the most member friction. They deserve review, not autopilot.
- Where are your maximums set, and when were they last looked at? A cap set years ago against a very different drug landscape can either expose the plan or fail members, and sometimes both.
Common questions
What is prescription drug coverage in Canada? Canada’s universal health insurance covers physician and hospital care, including drugs administered in hospital, but outpatient prescriptions filled at a pharmacy are largely outside it. That gap is filled by provincial and federal public drug programs, employer group plans, individual policies, and national pharmacare where it operates.
Does national pharmacare cover my prescriptions? Only if your province or territory has a bilateral agreement with the federal government. The first phase covers a range of birth control options and diabetes medications in British Columbia, Manitoba, Prince Edward Island and Yukon. It pays for listed products and the dispensing fee, but not delivery fees or pharmacist prescribing fees.
Is prescription drug coverage in Alberta part of national pharmacare? No. Alberta does not currently have a national pharmacare agreement. Drug coverage in Alberta runs through employer group plans, individual policies, and Alberta’s own government-sponsored programs such as Coverage for Seniors and Non-Group Coverage, which cover drugs listed in the Alberta Drug Benefit List.
What does a DIN number mean on a prescription? A Drug Identification Number is the eight-digit number Health Canada assigns to every drug sold in Canada. It identifies the manufacturer, product name and active ingredients, and appears on the product label and your pharmacy receipt. Private plans generally will not reimburse a product without a DIN.
Why did my plan only pay the generic price for a brand-name drug? Most plans apply generic substitution. Where an interchangeable generic exists, the plan reimburses at the generic price and the member pays the difference if they want the brand. Some plans allow an exception on documented medical grounds. Check your benefit booklet for the exception process.
Do Canadian drug plans cover weight-loss medications? Increasingly, though not universally. Survey data published by the International Foundation of Employee Benefit Plans in 2026 found 37% of Canadian employers cover GLP-1 therapies for both diabetes and weight loss, up from 17% in 2024, while 51% cover them for diabetes only. Where weight-management coverage exists it usually carries prior authorization and clinical eligibility criteria.
What is the difference between a biologic and a biosimilar? A biologic is a drug made from living cells. A biosimilar is a highly similar, lower-cost version available once the originator’s patent protection ends. Originator biologics can exceed $25,000 per patient per year, with biosimilars costing up to half as much.
Does Alberta’s biosimilar switching policy apply to my workplace plan? No. The Alberta Biosimilars Initiative applies only to Alberta government-sponsored drug programs, including Coverage for Seniors, Non-Group Coverage, Palliative Coverage, AISH and Income Support. It does not apply to private group plans. Employers with biologic coverage need their own biosimilar position.
What does prior authorization mean on a drug plan? Prior authorization means specified drugs require the insurer’s approval before they are covered, usually based on diagnosis, prior treatment history or clinical criteria. It is most common for specialty and high-cost drugs, and it is one of the main levers plans use to manage drug spend.
Let us look at your drug plan
Drug spend is usually the largest and least predictable line in a benefit plan. If you are heading into a renewal without a clear picture of what is driving yours, that is a conversation worth having before the numbers arrive rather than after.
Book a conversation with MP Benefits
Sources: Health Canada (national pharmacare coverage and participating jurisdictions), Alberta.ca (Coverage for Seniors; Non-Group Coverage), Alberta Blue Cross (Biosimilars Initiative; 2026 drug pipeline analysis), International Foundation of Employee Benefit Plans (2026 Canadian GLP-1 survey), Canadian Institute for Health Information (public drug spending).
Disclaimer: Please note that the information provided, while authoritative, is not guaranteed for accuracy and legality. The site is read by a world-wide audience and employment, taxation, legal vary accordingly. Please seek legal, accounting and human resources counsel from qualified professionals to make certain your legal/accounting/compliance interpretation and decisions are correct for your location. This information is for guidance, ideas, and assistance.
